-+ 0.00%
-+ 0.00%
-+ 0.00%

NurExone reports new preclinical data showing ExoPTEN boosts myelin marker in spinal cord injury model

PUBT·08/14/2026 12:59:20
Listen to the news
NurExone reports new preclinical data showing ExoPTEN boosts myelin marker in spinal cord injury model
  • NurExone disclosed new preclinical tissue-analysis results for ExoPTEN in an acute spinal cord injury animal model.
  • Findings were presented now, based on spinal cord samples from a previously reported efficacy study released on July 8, 2025.
  • Treated animals showed stronger signs of preserved nerve-fiber insulation versus controls, supporting a potential neuroprotective effect.
  • Data add biological support to earlier functional recovery results, strengthening the program’s case as it moves through preclinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140859PRIMZONEFULLFEED9810219) on August 14, 2026, and is solely responsible for the information contained therein.